IL210777A0 - Crystalline forms of a pyridine derivative - Google Patents

Crystalline forms of a pyridine derivative

Info

Publication number
IL210777A0
IL210777A0 IL210777A IL21077711A IL210777A0 IL 210777 A0 IL210777 A0 IL 210777A0 IL 210777 A IL210777 A IL 210777A IL 21077711 A IL21077711 A IL 21077711A IL 210777 A0 IL210777 A0 IL 210777A0
Authority
IL
Israel
Prior art keywords
crystalline forms
pyridine derivative
pyridine
derivative
crystalline
Prior art date
Application number
IL210777A
Other languages
English (en)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL210777A0 publication Critical patent/IL210777A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL210777A 2008-08-05 2011-01-20 Crystalline forms of a pyridine derivative IL210777A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
IL210777A0 true IL210777A0 (en) 2011-03-31

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210777A IL210777A0 (en) 2008-08-05 2011-01-20 Crystalline forms of a pyridine derivative

Country Status (14)

Country Link
US (1) US8093242B2 (cg-RX-API-DMAC7.html)
EP (1) EP2321324A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011529942A (cg-RX-API-DMAC7.html)
KR (1) KR20110052686A (cg-RX-API-DMAC7.html)
CN (1) CN102171219A (cg-RX-API-DMAC7.html)
AU (1) AU2009279135B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917224A2 (cg-RX-API-DMAC7.html)
CA (1) CA2733235A1 (cg-RX-API-DMAC7.html)
EA (1) EA201170300A1 (cg-RX-API-DMAC7.html)
GB (1) GB0814340D0 (cg-RX-API-DMAC7.html)
IL (1) IL210777A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011001414A (cg-RX-API-DMAC7.html)
WO (1) WO2010015626A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100426B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01292A (cg-RX-API-DMAC7.html) * 2009-08-27 2015-06-05 Glaxosmithkline Llc
SI3297631T1 (sl) * 2015-05-18 2019-12-31 Nerre Therapeutics Limited Antagonist NK-1/NK-3 receptorja za zdravljenje oblivov vročine
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
MX2022005867A (es) 2019-11-15 2022-06-14 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274604B1 (en) 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
HRP20070471T3 (hr) * 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
US7683056B2 (en) * 2005-09-09 2010-03-23 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders

Also Published As

Publication number Publication date
BRPI0917224A2 (pt) 2015-11-24
GB0814340D0 (en) 2008-09-10
AU2009279135A1 (en) 2010-02-11
KR20110052686A (ko) 2011-05-18
EA201170300A1 (ru) 2011-08-30
AU2009279135B2 (en) 2012-09-13
JP2011529942A (ja) 2011-12-15
CN102171219A (zh) 2011-08-31
EP2321324A1 (en) 2011-05-18
US20110136798A1 (en) 2011-06-09
CA2733235A1 (en) 2010-02-11
ZA201100426B (en) 2012-03-28
US8093242B2 (en) 2012-01-10
MX2011001414A (es) 2011-04-04
WO2010015626A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
SI2155200T1 (sl) Kristalinična oblika kabamoil-cikloheksanskega derivata
ZA201105479B (en) Pyridine derivative
ZA201008019B (en) A crystalline form of posaconazole
GB0819182D0 (en) Crystalline forms
SG10201500451TA (en) Crystalline forms of a purine derivative
IL212536A0 (en) Substituted pyridines having a herbicidal effect
EP2412708A4 (en) SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
EP2514747A4 (en) SUBSTITUTED AMINOTHIAZINE DERIVATIVE
IL214126A0 (en) Crystalline insulin-conjugates
IL206276A0 (en) Pyridine derivatives
ZA201100388B (en) Pyridine compounds
ZA201200812B (en) Anhydrate forms of a pyridine derivative
IL213466A0 (en) Spiroindolinone pyridine derivative
ZA201105045B (en) Crystalline forms of genistein
SI2358676T1 (sl) Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
IL210777A0 (en) Crystalline forms of a pyridine derivative
GB0902406D0 (en) Crystalline polymorphic form
SI2303866T1 (sl) Kristalne oblike natrijevega rabeprazolata
EP2243778A4 (en) piperidine
IL214028A0 (en) A novel cyanopyrimidine derivative
EP2285778A4 (en) NIKOTINAMIDDERIVATE
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
GB0812895D0 (en) Crystalline carbohydrate derivative
HU0800755D0 (en) Novel crystalline forms